8-K
filed February 23, 2023, 6:59 PM ET
ticker NVCR
CIK 0001645113
earnings
confidence high
sentiment neutral
materiality 0.70
NovoCure Q4 2022 net revenues $128.4M, full year $537.8M; LUNAR study meets primary endpoint
NovoCure Ltd
2022-FY EPS reported
-$0.88
revenue$537,840,000
- Full year 2022 net revenues $537.8M (+1% YoY); Q4 net revenues $128.4M (-4% YoY).
- Q4 net loss $37.3M ($0.36 loss per share); adjusted EBITDA $(10.5)M.
- Active patients 3,430 as of Dec 31, 2022 (-4% YoY); prescriptions 1,373 in Q4 (-4% YoY).
- Pivotal LUNAR study in NSCLC met primary overall survival endpoint; PANOVA-3 enrollment completed.
- Elected Dr. Allyson J. Ocean to Board of Directors; CE Mark for new array, limited market release in Europe.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NovoCure Ltd reported the fourth quarter ended December 31, 2022 results: revenue $128.4 million, net income $37.3 million, EPS $0.36 per share.
- Period
- the fourth quarter ended December 31, 2022
- Revenue
- $128.4 million
- Net income
- $37.3 million
- EPS
- $0.36 per share
- Result
- reported results
Exact text from the filing
Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of the pivotal
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NovoCure Ltd reported the fiscal year ended December 31, 2022 results: revenue $537.8 million.
- Period
- the fiscal year ended December 31, 2022
- Revenue
- $537.8 million
- Result
- reported results
Exact text from the filing
Total net revenues for the year were $537.8 million, an increase of 1% year-over-year.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.